Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
| Last: | $6.305 |
|---|---|
| Change Percent: | -0.86% |
| Open: | $6.23 |
| Close: | $6.36 |
| High: | $6.42 |
| Low: | $6.2123 |
| Volume: | 194,947 |
| Last Trade Date Time: | 03/16/2026 12:45:37 pm |
| Market Cap: | $418,750,104 |
|---|---|
| Float: | 38,506,803 |
| Insiders Ownership: | 0.06% |
| Institutions: | 27 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.zurabio.com |
| Country: | KY |
| City: | Henderson |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Zura Bio Limited (NASDAQ: ZURA).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
